FMS vs. NTRA, HIMS, OPCH, GH, RDNT, SHC, SGRY, BTSG, PRVA, and WGS
Should you be buying Fresenius Medical Care stock or one of its competitors? The main competitors of Fresenius Medical Care include Natera (NTRA), Hims & Hers Health (HIMS), Option Care Health (OPCH), Guardant Health (GH), RadNet (RDNT), Sotera Health (SHC), Surgery Partners (SGRY), BrightSpring Health Services (BTSG), Privia Health Group (PRVA), and GeneDx (WGS). These companies are all part of the "healthcare" industry.
Fresenius Medical Care vs.
Natera (NASDAQ:NTRA) and Fresenius Medical Care (NYSE:FMS) are both large-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, dividends, institutional ownership, valuation, profitability, community ranking and media sentiment.
Natera received 67 more outperform votes than Fresenius Medical Care when rated by MarketBeat users. Likewise, 68.92% of users gave Natera an outperform vote while only 54.72% of users gave Fresenius Medical Care an outperform vote.
Natera has a beta of 1.8, indicating that its share price is 80% more volatile than the S&P 500. Comparatively, Fresenius Medical Care has a beta of 0.99, indicating that its share price is 1% less volatile than the S&P 500.
Fresenius Medical Care has a net margin of 3.43% compared to Natera's net margin of -14.01%. Fresenius Medical Care's return on equity of 6.04% beat Natera's return on equity.
In the previous week, Natera had 18 more articles in the media than Fresenius Medical Care. MarketBeat recorded 24 mentions for Natera and 6 mentions for Fresenius Medical Care. Natera's average media sentiment score of 0.98 beat Fresenius Medical Care's score of 0.81 indicating that Natera is being referred to more favorably in the media.
99.9% of Natera shares are held by institutional investors. Comparatively, 8.4% of Fresenius Medical Care shares are held by institutional investors. 7.6% of Natera shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Fresenius Medical Care has higher revenue and earnings than Natera. Natera is trading at a lower price-to-earnings ratio than Fresenius Medical Care, indicating that it is currently the more affordable of the two stocks.
Natera currently has a consensus price target of $178.12, indicating a potential upside of 16.31%. Fresenius Medical Care has a consensus price target of $25.30, indicating a potential upside of 3.08%. Given Natera's stronger consensus rating and higher possible upside, equities research analysts plainly believe Natera is more favorable than Fresenius Medical Care.
Summary
Natera beats Fresenius Medical Care on 11 of the 18 factors compared between the two stocks.
Get Fresenius Medical Care News Delivered to You Automatically
Sign up to receive the latest news and ratings for FMS and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartMedia Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Fresenius Medical Care Competitors List
Related Companies and Tools
This page (NYSE:FMS) was last updated on 3/25/2025 by MarketBeat.com Staff